Gene therapy shows promise in ARC syndrome, a deadly childhood liver disease
· Medical Xpressedited by Stephanie Baum, reviewed by Robert Egan
Stephanie Baum
Scientific Editor
Meet our editorial team
Behind our editorial process
Robert Egan
Associate Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
A new gene therapy has been used to successfully treat a deadly childhood liver disease in mice that model the disease, according to researchers at UCL and Great Ormond Street Hospital. Arthrogryposis, renal dysfunction and cholestasis (ARC) syndrome is a lethal genetic disorder usually caused by a lack of the VPS33B protein, with children diagnosed with the condition rarely living beyond their first year of life.
Now, in a study published in Nature Communications, the UCL-GOSH team found that by injecting a healthy version of the gene into the body, they can treat the condition in mice lacking VPS33B. Crucially, the final version of the treatment, which specifically targeted the liver cells, caused no harm. In the earlier versions, the genes became abnormally activated and caused cancerous cells to grow and expand in some cases.
While more tests must be done before the treatment can be tested in humans, the researchers' breakthrough offers hope to babies with this devastating disorder and their families. In the UK, as many as six pregnancies per year might be affected by ARC syndrome. Furthermore, the findings may promote improved understanding of why some treatments may cause cancer.
Design shaped both benefit and risk
Lead author Dr. Claudiu Cozmescu (UCL Great Ormond Street Institute of Child Health) said, "Our findings are important because they provide proof of concept that gene therapy could become a realistic treatment for ARC syndrome and potentially other inherited liver diseases that currently have few or no effective options. They also highlight that how a gene therapy is designed is critical: Targeting treatment specifically to the liver improved safety while maintaining benefit.
"The findings should be of interest to patients and families affected by rare liver diseases, clinicians, gene therapy researchers, biotech developers, regulators and charities supporting rare disease research. Before human trials, further long-term toxicology and safety studies will be needed."
ARC syndrome is a medical condition in which the flow of bile from the liver is reduced or completely blocked. Bile is a digestive fluid produced by the liver to break down fats. When its flow is stalled, bile components (like bilirubin and bile acids) build up in the liver and leak into the bloodstream, leading to sepsis, which is usually fatal.
For the trial, the scientists used special mice that had been genetically engineered so that the VPS33B gene did not work properly. Some mice had no working copy of the gene in their liver (the "disease" mice), while others had only one working copy (which was used for safety testing). Because of this missing or faulty gene, the mice developed liver problems similar to those seen in children with ARC syndrome.
Early gains came with tumors
The researchers found that the treatment helped the mice's livers start working properly again: The mice lived longer (about 80% survived compared with about 33% that did not have the treatment), and their livers had less scarring (fibrosis).
The treatment was more effective when given throughout the body rather than just targeting the liver.
However, in the initial attempts to cure the disease, around 30% of those mice developed liver tumors—the risk of cancer developing as a side effect of gene therapy has been raised in previous trials.
But none of the mice treated with the final, liver-targeted version developed tumors, suggesting that gene therapy can be safe if done correctly.
Safety lessons beyond ARC syndrome
Co-author Professor Paul Gissen, clinical professor of pediatric metabolic medicine at UCL Great Ormond Street Institute of Child Health and director designate of the National Institute for Health and Care Research GOSH Biomedical Research Centre, said, "The final version of the treatment is shown to be safe so far. The earlier version gave us a new window into the understanding of how to make gene therapies safer for patients. One of these insights is to keep the levels of genes as close to those found in healthy cells as possible."
George Orphanides, chief scientific officer at LifeArc, added, "ARC syndrome is a serious, ultra-rare condition with very limited treatment options. These early findings are an important step toward understanding whether gene therapy could one day offer a new approach for affected children and their families.
"For many rare diseases, promising science can struggle to progress beyond the lab. LifeArc's rare disease work supports research into diseases with clear patient need and strong scientific potential to move closer to the point where it could make a difference, while ensuring safety is considered from the outset."
Publication details
Safety and efficacy analysis of in vivo lentiviral gene therapy in pre-clinical ARC syndrome models, Nature Communications (2026). DOI: 10.1038/s41467-026-73631-x
Journal information: Nature Communications
Key medical concepts
Gene TherapyLiver NeoplasmsLiver Fibrosis
Clinical categories
PediatricsChildren's healthGastroenterologyClinical geneticsClinical pharmacologyCommon illnesses & Prevention Provided by University College London Who's behind this story?
Stephanie Baum
Master's in TESOL from The New School. Passionate about language learning and editing science news on biology and space exploration. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Gene therapy shows promise in ARC syndrome, a deadly childhood liver disease (2026, June 19) retrieved 19 June 2026 from https://medicalxpress.com/news/2026-06-gene-therapy-arc-syndrome-deadly.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.